SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 27 Sep, 2014  

O2h to Provide Chemistry Support to Chromocell

PR Newswire | 23 Jun, 2011

CAMBRIDGE, England, AHMEDABAD, India and NORTH BRUNSWICK, New Jersey: Oxygen Healthcare Ltd. (O2h), a Piramal Group Company and Chromocell Corporation, an emerging life sciences company active in both flavors and therapeutics discovery, today signed an agreement under which O2h will provide supplemental chemistry support to further accelerate the drug discovery initiatives at Chromocell.

"I have known O2h for a number of years and am impressed by its delivery focus," said David Palling, Senior Vice President, Therapeutics, Chromocell. "With the in-house chemistry resources and the faster-than-expected progress made in our therapeutic programs, complementary support from O2h will help us maximize resources and reach our end-points quicker. I look forward to this opportunity of working with them to advance our drug discovery pipeline."

O2h will provide Chromocell during 2011 with focused libraries of compounds at mg-g scale for various projects.

Sunil Shah, CEO, O2h said "O2h has optimized its operations for discovery speed and delivery to help accelerate drug discovery efforts of companies in the United States, Europe and Japan. It is our privilege to work with the experienced team led by Dr. Palling at Chromocell,"

About Chromocell Corporation

Chromocell, founded in 2002 and headquartered in North Brunswick, N.J., is an emerging life sciences company which improves consumer products and patient lives through breakthrough science and technologies. It is focused on the discovery and development of both flavors and therapeutics through its pioneering Chromovert ® technology, a process that enables the company to use naturally occurring systems that mimic human biology as part of its discovery platform. Chromocell works with worldwide consumer goods companies to develop flavor ingredients and sweetness enhancers. Its therapeutics program is concentrated on pain relief, respiratory diseases, and other disorders where Chromovert technology offers the advantage of addressing complex and intractable targets. For more information, go to http://www.chromocell.com.

About O2h, a Piramal Group Company

O2h is the discovery services arm of Piramal Pharma Solutions Ltd, a top 10 global CRAMS group, offering a unique full-service partnership at every stage of the pharma life-cycle. Piramal Pharma Solutions employs 2,500 people across 9 specialist sites in North America, UK and India. The Piramal group has a 140 year history and is publicly listed company (BSE: PIRAMALHE).

O2h's 200 employees work within its project management office in Cambridge, UK and its operations in Ahmedabad India. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan.O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based medicinal, synthetic chemistry, and process chemistry as well as in vitro biology services. Further information on O2h can be found at http://www.o2h.com.

Contact:

Ekta Ahuja PhD
O2h
23, Cambridge Science Park
CB4 0EY
info@o2h.com

Barbara Shear
Chromocell Corporation
685 U.S. Highway One
North Brunswick, NJ 08902

SOURCE O2h

 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
PM Modi's recent US visit to redefine India-US bilateral relations
 Yes
 No
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter